Healthcare Billing Integrity
This group of stocks includes companies positioned to benefit from increased focus on healthcare billing compliance. Carefully selected by professional analysts, these stocks represent both healthcare tech providers offering compliance solutions and competing insurers who may gain market share amid regulatory scrutiny.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
The Cigna Corp
CI
Current price
$302.11
As a primary competitor to UnitedHealth, Cigna could attract new members from employer groups and individuals seeking a more trusted health insurance ...
As a primary competitor to UnitedHealth, Cigna could attract new members from employer groups and individuals seeking a more trusted health insurance provider amid the ongoing investigation.
Humana Inc.
HUM
Current price
$288.25
Humana, a major player in the Medicare Advantage market, is well-positioned to gain market share from UnitedHealth as seniors and other beneficiaries ...
Humana, a major player in the Medicare Advantage market, is well-positioned to gain market share from UnitedHealth as seniors and other beneficiaries may switch to insurers with a stronger reputation for compliance.
Elevance Health, Inc
ELV
Current price
$312.00
Elevance Health competes directly with UnitedHealth and could benefit from a flight to quality, capturing market share as customers and partners reass...
Elevance Health competes directly with UnitedHealth and could benefit from a flight to quality, capturing market share as customers and partners reassess their relationships with the embattled insurer.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
The DOJ investigation into UnitedHealth's Medicare billing practices signals a broader regulatory crackdown across healthcare. This creates opportunity for compliance software providers and competing insurers with strong records. Companies in this group are positioned to benefit from increased compliance spending and potential market share shifts.
What You Need to Know
This collection includes two types of companies: health-tech firms providing compliance software and auditing tools, and rival insurers with strong compliance records. This represents a tactical, event-driven portfolio aimed at capturing a specific opportunity within the healthcare sector following increased scrutiny.
Why These Stocks
These companies were specifically selected to capture the dual opportunities created by the DOJ probe: the increased demand for compliance technology and the potential for market share shifts among insurance providers. Each company offers exposure to either the technology enabling compliance or the possibility of gaining customers from competitors under scrutiny.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+77.36%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 77.36% over the next year.
Stocks Rated Buy by Analysts
12 of 15 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 2.7% return last month.
Why You'll Want to Watch These Stocks
Regulatory Spotlight Creates Opportunity
Healthcare billing practices are under intense scrutiny from regulators, creating a perfect environment for companies with strong compliance solutions and clean records to thrive.
Non-Discretionary Tech Spending Boom
Healthcare organizations are now prioritizing compliance software as a must-have expense, not a luxury. This means steady, growing demand for the tech companies in this group.
Market Share Shifts Happening Now
As patients and employers lose confidence in insurers under investigation, competitors with strong reputations stand to gain millions of new members and billions in revenue.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.